A study of the reproducibility of a fluorescence in situ hybridization bladder cancer detection assay

Analytical and Quantitative Cytology and Histology

Volumn 30, Issue 3, 2008, Pages 145-151

  Brankley, Shannon M ^a   Adams, Elizabeth J ^a   Christensen, Michael R ^a   Everts, Cortney R ^a   Lund, Jennifer D ^a   Oberg, Trynda N ^a   Plagge, Amy M ^a   Zieman, Angela H ^a   Kipp, Benjamin R ^a   Halling, Kevin C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer, bladder; Cells, urothelial; Fluorescence in situ hybridization

Indexed keywords

ARTICLE; BLADDER CANCER; CYTOTECHNOLOGIST; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; INTERRATER RELIABILITY; PRIORITY JOURNAL; REPRODUCIBILITY;

CARCINOMA, TRANSITIONAL CELL; CHROMOSOME ABERRATIONS; DNA, NEOPLASM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 44949221327     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson SL, Lieber M, Soloway M, Flom K: Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950-1954
2. Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, Jansz K, Bridge JA, Johansson SL, Persons DL, Gibson JS: Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006;176:44-47
3. Kipp BR: Quantitative fluorescence in situ hybridization for predicting bladder cancer recurrence and progression to muscle-invasive disease (abstr). Cancer Cytopathol 2007;111:419-420
4. Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, Blute MM, Lieber MM, Zincke H, Halling KC: Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005;173:401-404
5. Inc AM: UroVysion Bladder Cancer Kit (package insert). Des Plaines, IL, 2006
6. Kipp BR, Campion MB, Coffman E, Smith A, Tomisek JD, Browne GG, Panella JR, Desai R, Harwood AR, Halling KC: An evaluation of ThinPrep UroCyte filters for the preparation of slides for fluorescence in situ hybridization. Diagn Cytopathol 2006;34:479-484
7. Kipp BR, Fritcher EG, del Rosario KM, Stevens CL, Sebo TJ, Halling KC: A systematic approach to identifying urothelial cells likely to be polysomic by fluorescence in situ hybridization. Anal Quant Cytol Histol 2005;27:317-322
8. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W: The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2:116-123
9. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, Cheville JC, Sebo TJ, Ramakumar S, Stewart CS, Pankratz S, O'Kane DJ, Seelig SA, Lieber MM, Jenkins RB: A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768-1775
10. Davidson DD, Cheng L: "Field cancerization" in the urothelium of the bladder. Anal Quant Cytol Histol 2006;28:337-338
11. Halling KC: Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003;3:507-519